Arthur T. Sands

Company: Nurix Therapeutics, Inc

Job title: President & CEO

Seminars:

The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic 10:00 am

• Nurix has advanced two targeted protein degraders of Bruton’s Tyrosine Kinase (BTK) into Phase 1 clinical trials – NX-2127 and NX-5948 • Degradation offers key advantages over inhibition to address the unmet need of treatment-emergent drug resistance mutations • An update from the ongoing Phase 1 programs will be presented For more information on…Read more

day: Day One